Key Highlights
- LQDA shares rose 7.66% to $73.67 at Monday's close on September 28, 2026, while the Russell 2000 slipped 0.69%.
- Liquidia is a biopharmaceutical company focused on cardiopulmonary disease, best known for its work in pulmonary hypertension.
- Companies in this niche depend on the progress of lead therapies, and sector sentiment can amplify moves.
- MBX Biosciences, AbCellera and NewAmsterdam Pharma also finished higher while the major US indexes closed lower.
Shares of Liquidia (NASDAQ:LQDA) ended Monday, September 28, 2026 higher by 7.66%, at $73.67. The biopharmaceutical company is best known for its work in pulmonary hypertension, a serious condition affecting the blood vessels of the lungs.
Latest Developments
LQDA shares gained at Monday's close in a session when the major US indexes fell.
Liquidia is a biopharmaceutical company focused on treatments for cardiopulmonary disease, best known for its work in pulmonary hypertension.
Financial and Business Position
Companies in this niche depend on the progress of their lead therapies, and sentiment toward the biotech group can amplify moves.
Companies in this niche live and die by the progress of their lead therapies, the regulatory path they navigate, and their ability to compete against established products, which makes their shares sensitive to clinical, commercial and legal developments. Rising long-term yields tend to weigh on development- and commercial-stage biotech alike, since so much of the value in these names is tied to future cash flows. The company has been closely followed for developments around its pulmonary-hypertension franchise, including commercial progress and the competitive and legal dynamics that surround products in that space, any of which can move the shares when fresh news lands.
Stock-Market Context
Equity benchmarks in the US finished lower on Monday, September 28: the S&P 500 by 0.77% to 7,683.69, the Dow by 0.67% to 51,481.51 and the Nasdaq Composite by 0.92% to 26,820.38.
Treasury yields pushed higher, with the 10-year note above 5.2% for a multi-year high, and oil prices rose as US-Iran talks stalled after a rejected Iranian proposal.
MBX Biosciences (NASDAQ:MBX), AbCellera (NASDAQ:ABCL) and NewAmsterdam Pharma (NASDAQ:NAMS) also finished higher.
Liquidia, as an established player in a defined therapeutic area, is the kind of name that can benefit from that renewed appetite even on a broadly negative day for equities. It also helps to remember that biotech frequently trades on its own clock.
Pulmonary Hypertension in a Firmer Biotech Group
Liquidia closed Monday higher with other biotech names in a session when the indexes fell. Its pulmonary hypertension focus frames the stock.






Please wait processing your request...